PATENT CLAIM ANALYSIS

Application Number: 15766642
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["514", "007600"]

Abstract:
Dosing regimens and methods are disclosed for upregulating on protein kinase C (PKC) while reducing subsequent downregulation, comprising administering a PKC activator once a week for three consecutive weeks followed by cessation of administration or dosing for three consecutive weeks. Also described are methods for improving or enhancing cognitive ability, preventing or treating cognitive impairment, preventing or treating a neurodegenerative disease or condition, and/or preventing or treating a disease or condition associated with neuronal or synaptic loss according to the disclosed regimens.

Claim (Index 11):
The method according to  claim 10 , wherein the neurodegenerative disorder is chosen from Alzheimer's disease, chronic traumatic encephalopathy (CTE), Parkinson's disease, multiple sclerosis, traumatic brain injury, Fragile X, Niemann-Pick C, frontotemporal dementia, vascular dementia, depression, bipolar disorder, schizophrenia, Post-Traumatic Stress Disorder, stroke, mental retardation, or brain injury.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 91.0
- Lexical Diversity: 1.55172
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13817040', '13178843', '14818576', '14357654', '13669353']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7537222898771122
- 35 USC 102 Novelty (BERT): 0.5327751621611228
- Combined Prediction Score: 0.7316275771055133
- Mean Citation Score: 300.23155799999995
- Max Citation Score: 345.7514
- Similarity Product: 201.3516511483312

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test